General discussion, page-19981

Good post @flanostu

I definitely concur with you sentiment. I try to separate the Corporate arm from the pharmaceutical arm. Extremely confident with the pharmaceutical arm but the corporate arm clearly are showing issues on a number of fronts.

Lack of marketing, branding, updates, keeping current shareholders informed with benchmarks, cost of the corporate arm and increases in those costs and the lack so far in portfolio value. In fact the Redomicile has decimated portfolio wealth

I hope the success in our pharmaceutical arm will override the corporate arm and this in turn will begin to attract investors especially institutional.

All the best mate